Rituximab in the Management of a Child with Pemphigus Vulgaris: Case Study

Background. Pemphigus vulgaris is an autoimmune bullous dermatosis. Its management generally involves lifelong administration of maintenance dose of systemic glucocorticosteroids, that leading to serious adverse effects especially in children.

Clinical case description. Patient is the 16 years old boy with severe course of pemphigus vulgaris. The diagnosis was confirmed by the results of cell smear study from fresh erosions (> 50 acantholytic cells were revealed), histological examination of the skin biopsy from the lesion with the vesicle element (suprabasal vesicle was localized in the center, it included fibrin, neutrophil granulocytes, and acantholytic cells), skin biopsy from the area near the lesion (visually healthy skin), via direct immunofluorescence methods (IgG deposition was detected on keratinocytes’ surface throughout the epidermis), and enzyme-linked immunosorbent assay (desmoglein 1 IgG autoantibodies — 121 U/mL (reference value < 20 U/mL) and desmoglein 3 — > 200 U/mL (reference value < 20 U/mL)). Genetically engineered biologic drug, rituximab, and systemic glucocorticosteroid, methylprednisolone, were prescribed as first-line therapy with gradual dose reduction to permanent discontinuation in 8 months. Complete remission maintained after the completion of therapy course and discontinuation of systemic glucocorticosteroid.

Conclusion. Combined therapy with systemic glucocorticosteroids and rituximab can be considered as first-line therapy in pediatric patients with pemphigus vulgaris due to relatively low risk of recurrence after rather rapid and complete drugs’ discontinuation.

1. Hartwig NG, Oranje AP, Gysel DV, van Praag MCG. Acquired Neonatal Infections. In: Harper’s Textbook of Pediatric Dermatology. Irvine AD, Hoeger PH, Yan AC, eds. 3rd ed. Blackwell Publishing Ltd.; 2011. pp. 91.1–91.5. doi: https://doi.org/10.1002/9781444345384

2. Kang S, Amagai M, Bruckner AL, et al. In: Fitzpatricks Dermatology. 9th ed. MGH; 2019. pp. 910–925.

3. Beutner EH, Jordon RE. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent stai ning. Proc Soc Exp Biol Med. 1964;117:505–510. doi: https://doi.org/10.3181/00379727-117-29622

4. Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255–270. doi: https://doi.org/10.1007/s12026-018-8986-7

5. Egami S, Yamagami J, Amagai M. Autoimmune bullous skin dise ases, pemphigus and pemphigoid. J Allergy Clin Immunol. 2020;145(4): 1031–1047. doi: https://doi.org/10.1016/j.jaci.2020.02.013

6. Patel MH, Brumfiel CM, Bohrer N, Marsch AF. Efficacy of rituximab in pediatric pemphigus: A literature review. JAAD Int. 2021;6:6–10. doi: https://doi.org/10.1016/j.jdin.2021.10.002

7. Fuertes I, Guilabert A, MascaroJM Jr, Iranzo JP. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. Dermatology. 2010;221(1):13–16. doi: https://doi.org/10.1159/000287254

8. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882–894. doi: https://doi.org/10.1016/s0140-6736(19)31778-7

9. Melchionda V, Harman KE. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management. Clin Exp Dermatol. 2019; 44(7):740–746. doi: https://doi.org/10.1111/ced.14041

10. Porro AM, Seque CA, Ferreira MCC, Enokihara MMSS. Pemphigus vulgaris. An Bras Dermatol. 2019;94(3):264–278. doi: https://doi.org/10.1590/abd1806-4841.20199011

11. Suliman NM, Åstrøm AN, Ali RW, et al. Clinical and histological characterization of oral pemphigus lesions in patients with skin diseases: a cross sectional study from Sudan. BMC Oral Health. 2013;13(1):66. doi: https://doi.org/10.1186/1472-6831-13-66

12. Puzyrchatka: Clinical guidelines. Russian Society of Dermatologists and Cosmetologists; 2016. 26 p. (In Russ). Доступно по: https://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii2017. Ссылка активна на 29.09.2022

13. Vinay K, Kanwar AJ, Sawatkar GU, et al. Successful use of rituximab in the treatment of childhood and juvenile pemphigus. J Am Acad Dermatol. 2014;71(4):669–675. doi: https://doi.org/10.1016/j.jaad.2014.05.071

14. Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and Future Therapeutic Strategies. Front Immunol. 2019;10:1418. doi: https://doi.org/10.3389/fimmu.2019.01418

15. Joly P, Horvath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900–1913. doi: https://doi.org/10.1111/jdv.16752

16. Joly P, Maho-Vaillant M, Prost-Squarcioni C. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–2040. doi: https://doi.org/10.1016/s0140-6736(17)30070-3

17. Boulard C, Duvert Lehembre S, Picard-Dahan C, et al. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol. 2016;175(1): 142–149. doi: https://doi.org/10.1111/bjd.14405

18. Lins GT, Barbosa NLS, de Abreu EMV, et al. Childhood pemphigus vulgaris is a challenging diagnosis. Autops Case Rep. 2021;11:e2021267. doi: https://doi.org/10.4322/acr.2021.267

19. Surya V, Kumar P, Gupta S, Urs AB. Childhood pemphigus vulgaris: report of two cases with emphasis on diagnostic approach. Contemp Clin Dent. 2018;9(Suppl 2):S373–S376. doi: https://doi.org/10.4103/ccd.ccd_461_18

20. Kincaid L, Weinstein M. Rituximab therapy for childhood pemphigus vulgaris. Pediatr Dermatol. 2016;33(2):e61–e64. doi: https://doi.org/10.1111/pde.12744

21. Joly P, Mouquet H, Roujeau J-C, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6): 545–552. doi: https://doi.org/10.1056/NEJMoa067752

22. Ingen-Housz-Oro S, Valeyrie-Allanore L, Cosnes A, et al. First-line treatment of pemphigus vulgaris with a combination of rituxi mab and high-potency topical corticosteroids. JAMA Dermatol. 2015;151(2):200–203. doi: https://doi.org/10.1001/jamadermatol.2014.2421

23. Bilgic-Temel A, Özgen Z, Harman M, et al. Rituximab therapy in pediatric pemphigus patients: a retrospective analysis of five Turkish patients and review of the literature. Pediatr Dermatol. 2019;36(5):646–650. doi: https://doi.org/10.1111/pde.13926